NASDAQ:NOVN - Novan Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: -76.01 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.45 (-4.14%)

This chart shows the closing price for NOVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novan Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NOVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NOVN

Analyst Price Target is $2.50
▼ -76.01% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Novan in the last 3 months. The average price target is $2.50, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a -76.01% upside from the last price of $10.42.

This chart shows the closing price for NOVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Novan. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/4/2021HC WainwrightBoost Price TargetBuy$1.50 ➝ $2.00High
4/22/2021Roth CapitalInitiated CoverageBuy$3.00High
5/26/2020HC WainwrightReiterated RatingBuy$1.50Low
1/6/2020HC WainwrightReiterated RatingBuy$6.00 ➝ $1.50N/A
1/5/2020Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$0.50N/A
3/29/2019JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
12/10/2018HC WainwrightSet Price TargetBuy$6.00High
11/16/2018HC WainwrightSet Price TargetBuy$8.00Low
11/6/2018HC WainwrightReiterated RatingBuy$8.00Medium
10/26/2018HC WainwrightInitiated CoverageBuy$8.00Low
7/20/2018Piper Jaffray CompaniesReiterated RatingBuy$6.00High
5/21/2018JMP SecuritiesSet Price TargetBuy$14.00Low
9/25/2017WedbushReiterated RatingNeutral$6.00High
8/3/2017Piper Jaffray CompaniesReiterated RatingBuyLow
4/12/2017Piper Jaffray CompaniesSet Price TargetBuy$11.00Low
4/12/2017WedbushReiterated RatingNeutral$8.00High
3/20/2017WedbushReiterated RatingNeutral$8.00High
3/6/2017WedbushReiterated RatingNeutral$8.00N/A
1/27/2017WedbushDowngradeOutperform ➝ Neutral$6.00 ➝ $33.00N/A
11/29/2016WedbushReiterated RatingOutperform$33.00N/A
11/14/2016WedbushReiterated RatingOutperform$27.00N/A
10/17/2016Credit Suisse GroupInitiated CoverageOutperform$27.00 ➝ $18.97N/A
10/17/2016JMP SecuritiesInitiated CoverageOutperform$31.00N/A
10/17/2016WedbushInitiated CoverageOutperform$27.00N/A
10/17/2016Piper Jaffray CompaniesInitiated CoverageOverweight$25.00N/A
(Data available from 6/21/2016 forward)
Novan logo
Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $10.42
Low: $10.16
High: $11.13

50 Day Range

MA: $4.43
Low: $0.84
High: $17.35

52 Week Range

Now: $10.42
Low: $3.00
High: $25.90


100,362 shs

Average Volume

2,902,270 shs

Market Capitalization

$158.08 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Novan?

The following equities research analysts have issued reports on Novan in the last year: HC Wainwright, and Roth Capital.
View the latest analyst ratings for NOVN.

What is the current price target for Novan?

2 Wall Street analysts have set twelve-month price targets for Novan in the last year. Their average twelve-month price target is $2.50, suggesting a possible downside of 76.1%. Roth Capital has the highest price target set, predicting NOVN will reach $3.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.00 for Novan in the next year.
View the latest price targets for NOVN.

What is the current consensus analyst rating for Novan?

Novan currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NOVN will outperform the market and that investors should add to their positions of Novan.
View the latest ratings for NOVN.

What other companies compete with Novan?

How do I contact Novan's investor relations team?

Novan's physical mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company's listed phone number is (919) 485-8080 and its investor relations email address is [email protected] The official website for Novan is